Tradestie Institutional Equity Comparison Engine

CLYM vs COCP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“0 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus COCP at N/M Forward P/E and -3063.6% operating margin (+26.9% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against COCP sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CLYM N/M vs COCP N/M Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs -3063.6% ยท YoY +0.0% vs +26.9%
Momentum & Technical Winner CLYM
1Y +414.7% vs -1.9% ยท 52W Pos 49% vs 20%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.78
-1.61% 1D
Market Cap $608.5M
1M Return +0.51%
1Y Return +414.74%
Forward P/E N/M
Unified AI Score
45.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 54.0
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.3% 1D
Market Cap $18.9M
1M Return +6.7%
1Y Return -1.94%
Forward P/E N/M
Unified AI Score
38.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLYM +414.74% COCP -1.94% Spread: +416.68 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLYM TTM Op. Margin: 0.0% COCP TTM Op. Margin: -3063.6%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs COCP. Trailing 12-month operating profitability (CLYM 0.0% vs COCP -3063.6%) and valuation multiples (CLYM N/M vs COCP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLYM (5) vs COCP (2)
Institutional Metric CLYM COCP Criterion Row Winner
Market Capitalization Scale $608.5M $18.9M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +26.9% Higher Growth COCP
Operating Margin (TTM) Profitability 0.0% -3063.6% Higher Margin CLYM
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -29.3% -311.7% Higher ROE CLYM
52-Week Range Position Momentum 49% ($2โ€“$18) 20% ($1โ€“$2) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 112% Vol 0.98ฮฒ ยท 54% Vol Lower Realized Risk COCP
Unified Institutional Score Composite Signal 45.7 / 100 (HOLD) 38.7 / 100 (SELL) Higher Composite CLYM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLYM vs COCP Buy Guide
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live COCP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLYM nor COCP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.